Letters

Sentinel node biopsy in breast cancer

BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7183.599 (Published 27 February 1999) Cite this as: BMJ 1999;318:599

Effect on patients must be considered

  1. Hazel Thornton, Chairman, Consumers' Advisory Group for Clinical Trials (Hazelcagct@aol.com)
  1. Saionara, Rowhedge, Colchester CO5 7EA
  2. Sarcoma and Melanoma Unit, Royal Marsden NHS Trust, London SW3 6JJ
  3. Guy's and St Thomas's Breast Unit, Guy's and St Thomas's Hospitals, London
  4. Academic Office, Edinburgh Breast Unit, Western General Hospital, Edinburgh, EH4 2XU

    EDITOR—Careful consideration needs to be given to the implications for breast cancer patients from the use of the unevaluated technique of sentinel node biopsy.1 Ideally, clinical trials to refine this technique should have been done before its introduction into routine clinical practice by enthusiastic surgeons. Training courses and conferences on this topic must be timed to avoid encouraging premature introduction and wasting resources.

    The possibility that sentinel node biopsy would avoid clearance of the axilla, with its attendant problems, could be seductive to both surgeons and patients. The technique holds promise of clearer prognosis and swifter assessment with minimum invasiveness. What then might the drawbacks be for patients? Consideration of the best total outcome for the patient must always be the overriding objective.

    It might be useful to draw a parallel between the introduction of mammographic screening, which resulted in closer scrutiny of breast tissue, and the use of sentinel node biopsy. Screening caused the label “breast cancer” to be applied to borderline cases so that many women with non-invasive conditions which would never cause them problems in their lifetime carried the “cancer” label with all its drawbacks, emotional and financial. By the same token, closer scrutiny of the sentinel node will cause an upstaging of the disease. Techniques such as step sections, immunostaining, and polymerase chain reaction (which can detect 1in 10000 cancer cells) “metastatic” is applied more readily, with enormous implications for the women given that label.

    Foucar commented on the surprising docility of patients about the pathologist's monopoly on diagnostic terminology that links objective histopathological observations to clinical interventions.2 Classifications resulting from the use of sentinel …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe